Robert Perttilä

Robert Perttilä

Auto-generated profile, based on publicly available information

Robert Perttilä

Modulight Corporation, Tampere, Finland

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Molecular Cell
Verified
Journal Article
Closed access
JSJoshua B. Sheetz
Joshua B. Sheetz
SMSebastian Mathea
Sebastian Mathea
HKHanna Karvonen
Hanna Karvonen
KMKetan Malhotra
Ketan Malhotra
DCDeep Chatterjee
Deep Chatterjee
MLMark A. Lemmon
Mark A. Lemmon

10 January 2019 in Oncogene
Verified
Journal Article
Closed access
PDF file
HKHanna Karvonen
Hanna Karvonen
RPRobert Perttilä
Robert Perttilä
WNWilhelmiina Niininen
Wilhelmiina Niininen
VHVeera Hautanen
Veera Hautanen
HBHarlan Barker
Harlan Barker
DUDaniela Ungureanu
Daniela Ungureanu

23 August 2019 in Photochemistry and Photobiology
Verified
Journal Article
Closed access
PDF file
CICollin T. Inglut
Collin T. Inglut
BGBrandon Gaitan
Brandon Gaitan
DNDaniel Najafali
Daniel Najafali
ILIrati Abad Lopez
Irati Abad Lopez
NCNina P. Connolly
Nina P. Connolly
HHHuang Chiao Huang
Huang Chiao Huang

8 September 2023 in Science Advances
Verified
Journal Article
Open access
BLBarry J. Liang
Barry J. Liang
SPSumiao Pang
Sumiao Pang
RPRobert Perttila
Robert Perttila
CMChen-Hua Ma
Chen-Hua Ma
PSPayal Srivastava
Payal Srivastava
HHHuang Chiao Huang
Huang Chiao Huang
Fluorescence-guided intervention can bolster standard therapies by detecting and treating microscopic tumors before lethal recurrence. Tremendous progress in photoimmunotherapy and nanotechnology has been made to treat metastasis. However, many are lost in translation due to heterogeneous treatment effects. Here, we integrate three technological advances in targeted photo-activable multi-agent liposome (TPMAL), fluorescence-guided intervention, and laser endoscopy (ML7710) to improve photoimmunotherapy. TPMAL consists of a nanoliposome chemotherapy labeled with fluorophores for tracking and photosensitizer immunoconjugates for photoimmunotherapy. ML7710 is connected to Modulight Cloud to capture and analyze multispectral emission from TPMAL for fluorescence-guided drug delivery (FGDD) and fluorescence-guided light dosimetry (FGLD) in peritoneal carcinomatosis mouse models. FGDD revealed that TPMAL enhances drug delivery to metastases by 14-fold. ML7710 captured interpatient variability in TPMAL uptake and prompted FGLD in >50% of animals. By combining TPMAL, ML7710, and fluorescence-guided intervention, variation in treatment response was substantially reduced and tumor control improved without side effects.

10 July 2018 in European Journal of Haematology
Verified
Journal Article
Open access
PDF file
HKHanna Karvonen
Hanna Karvonen
RPRobert Perttilä
Robert Perttilä
WNWilhelmiina Niininen
Wilhelmiina Niininen
HBHarlan Barker
Harlan Barker
DUDaniela Ungureanu
Daniela Ungureanu
Recent studies showed that several pseudokinases from the receptor tyrosine kinase family are important players in regulating cancer cell invasion, metastasis, and drug resistance, suggesting that targeting these proteins can play a therapeutic role in cancer treatment. Receptor Tyr kinase‐like orphan receptors (RORs), protein Tyr kinase 7 (PTK7) (also called colon carcinoma kinase 4 (CCK4)), and receptor‐like Tyr kinase (RYK) are Wnt ligand binding receptors within the non‐canonical Wnt signaling, with important roles in development, tissue homeostasis, and organogenesis. At the cellular level, these receptors transduce signals important for cell survival, migration, polarization, and chemotaxis. Considerable progress has been made in the last decade in the field of pseudokinase signaling, improving our understanding of their structure‐function mechanisms, and intracellular network of transduction components. Consequently, their role in various diseases, including cancer, is now scrutinized for therapeutic interventions to improve treatment outcome. In this article, we review findings regarding molecular mechanisms and targeted therapies for ROR1, PTK7, and RYK in hematological malignancies.